Phase 3 Autism Spectrum Disorder Trial, Recruiting NCT07450443 Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Phase 3 Autism Spectrum Disorder Trial, Recruiting

NCT07450443
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For Groups 1 and 2 (children with autism and gut symptoms):

  • The child has been diagnosed with autism spectrum disorder (ASD) based on recognised medical guidelines (DSM-5)
  • The child has been assessed by a specialist children's neurologist and neuropsychologist using standard autism assessment tools
  • The child has had their developmental or intellectual level assessed using recognised standardised tests
  • In the past three months, the child has experienced gut-related symptoms such as constipation, diarrhoea, unusual stools, gas, stomach pain, unexplained daytime irritability, night waking, or stomach tenderness — and scored at least 2 on at least one gut symptom on a specific questionnaire (confirm with trial site)
  • A parent or guardian has signed a consent form agreeing to gut microbiome and metabolite testing and to the child taking a supplement called PostbiotiX Comfort ®

For Group 3 (typically developing children without gut symptoms):

  • The child is a boy or girl aged between 3 and 8 years old with typical development and no gut symptoms
  • A parent or guardian has signed a consent form agreeing to gut microbiome and metabolite testing

Who may not be able to join:

For Groups 1 and 2:

  • Children whose autism is linked to a known genetic condition or syndrome
  • Children who have serious health problems that require surgery or ongoing medical treatment
  • Children with severe gut problems that need urgent or emergency treatment
  • Children who are severely underweight or malnourished
  • Children who have taken antibiotics or probiotic/prebiotic supplements within the month before joining the trial

For Group 3:

  • Children who have gut problems needing urgent or emergency treatment, or who have ongoing gut symptoms such as chronic constipation or diarrhoea, bowel accidents, recurring bloating or stomach pain, acid reflux, vomiting, or strong food aversions

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Stefano D'Arrigo, MD, Fondazione IRCCS Istituto Neurologico Carlo Besta

Phone: + 39 02.2394

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Registry
ClinicalTrials.gov
Start date
21 March 2023
Est. completion
1 December 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Modulation of Gastrointestinal Symptoms in ASD with Postbiotic Supplement

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov